Medivir's TMC435 will be evaluated in a phase II combination study with daclatasvir (BMS 790052) for HCV genotype-1 patients
Medivir AB announced that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company. TMC435, a once daily NS3/4A protease inhibitor (PI) for the treatment of genotype-1 chronic hepatitis C virus (HCV) infection will be investigated in combination with Bristol-Myers Squibb´s investigational NS5A replication complex inhibitor, daclatasvir.
Charlotte Edenius, Executive VP Research & Development, of Medivir commented, "We are very excited to work with Bristol-Myers Squibb to investigate our protease inhibitor, TMC435, in combination with an NS5A replication complex inhibitor to enable the advancement of novel treatment options for people chronically infected with HCV. We believe that an all oral, treatment regimen for HCV would represent a major step towards improved HCV treatments.”
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Teva announces successful results of Phase III with oral laquinimod for multiple sclerosis
Cenix BioScience and ugichem sign research agreement on development of novel gene silencing technology.
Lead exposure linked to ADHD in kids with genetic mutation

Metastasis: Cell polarity matters
Ipomoea_tricolor

No more 'superbugs'? - Maple syrup extract enhances antibiotic action

First-of-its-kind biofabrication research lab opens at University of Illinois
Plant light sensors came from ancient algae
Molecular 'firing squad' in mice triggered by overeating destroys metabolism
Cerenis Reports Positive Results for Phase 1 Study of CER-001, an HDL mimetic, for the Treatment of Cardiovascular Disease
